Idexx Laboratories Inc
Q1 2022 Earnings
Market Reaction
S&P 500 over the same 30 days: −4.03%.
Did IDXX Beat Earnings? Q1 2022 Results
IDEXX Laboratories posted a narrow earnings beat for Q1 2022 but fell just short on the top line, as strong companion animal diagnostics momentum ran up against a meaningful drag from its livestock business. The company reported EPS of $2.27, edging past the consensus estimate of $2.26 by 0.44%, while revenue of $836.55 million missed the $839.72 million consensus by 0.38%, though it still grew 7.6% year over year. The primary weight on results came from a 21% reported decline in Livestock, Poultry and Dairy revenues, driven by unfavorable comparisons to prior-year African Swine Fever testing programs in China, which offset otherwise solid 8% organic growth in CAG Diagnostics recurring revenue. Operating margin contracted 220 basis points to 29.7% as the company accelerated investment in commercial capabilities. Looking ahead, IDEXX meaningfully trimmed its full-year 2022 EPS outlook to $8.11 to $8.35, reflecting roughly $80.00 million in discrete Q2 R&D licensing costs, currency headwinds, and moderated veterinary clinic visit growth, while projecting revenue of $3.39 billion to $3.47 billion.
- Record first quarter premium instrument placements globally
- High single-digit organic growth in CAG Diagnostics recurring revenues building on strong prior year
- Strong growth in cloud-based software placements
- Net price gains and high customer retention levels across modalities
- Same-store volume growth and new business gains in reference laboratory services
- Continued solid recovery in water testing demand
“IDEXX's first quarter results build on the significant gains in demand for companion animal diagnostics and software solutions achieved over the last two years. Veterinarians and their staffs continue to work passionately to support their practices in a demanding environment. IDEXX solutions help to improve patient care and manage increased demands on their time, as well as to continue to advance higher standards for pet healthcare, including utilization of diagnostics. This is reflected in continued strong IDEXX premium instrument placements globally, expansion of our cloud-based software solutions and high single-digit organic growth in CAG Diagnostics recurring revenues compared to very strong prior year growth levels. These results demonstrate the benefits of our ongoing focus on innovation, the continued high level of customer-focused execution of IDEXX teams globally and our commitment as a purpose-driven company to improving the health and well-being of pets, people and livestock.”
IDEXX Laboratories CEO, on the earnings call
Forward Guidance & Outlook
IDEXX recalibrated its full year 2022 outlook, projecting revenue of $3,390M-$3,465M, reflecting 5.5%-8% reported growth and 7.5%-10% organic growth. The revision accounts for moderated veterinary clinical visit growth from constraints on clinic capacity, ~$10M revenue reduction from the war in Ukraine, and ~$40M impact from the strengthened U.S. dollar. CAG Diagnostics recurring revenue organic growth is projected at 9%-11%. Full year operating margins are projected at 26.8%-27.3%, including a 230 basis point negative impact from ~$80M of discrete R&D expense for in-licensing of intellectual property in Q2. EPS outlook is $8.11-$8.35, reduced by ~$1.20 at midpoint ($0.72 from discrete R&D, $0.10 from FX, $0.05 from higher interest rates). Operating cash flow is projected at 90%-95% of net income, free cash flow at 65%-70% of net income, with capital expenditures of ~$180M.
IDXX YoY Financials
IDXX Revenue by Segment
IDXX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.